Compare ALCO & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALCO | HELP |
|---|---|---|
| Founded | 1960 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.7M | 281.4M |
| IPO Year | 1994 | N/A |
| Metric | ALCO | HELP |
|---|---|---|
| Price | $40.61 | $4.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $44.00 | ★ $95.00 |
| AVG Volume (30 Days) | 26.6K | ★ 1.1M |
| Earning Date | 05-12-2026 | 07-01-2026 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.61 | $4.41 |
| 52 Week High | $43.20 | $8.55 |
| Indicator | ALCO | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 35.50 |
| Support Level | $39.99 | $4.47 |
| Resistance Level | $42.58 | $4.95 |
| Average True Range (ATR) | 1.30 | 0.34 |
| MACD | 0.20 | -0.03 |
| Stochastic Oscillator | 71.10 | 7.19 |
Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.